공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

농가진 : 파이프라인 리뷰

Impetigo (Infectious Disease) - Drugs in Development, 2021

리서치사 Global Markets Direct
발행일 2021년 09월 상품 코드 360913
페이지 정보 영문 45 Pages
가격
US $ 2,000 ₩ 2,395,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,790,000 PDF (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,185,000 PDF (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


농가진 : 파이프라인 리뷰 Impetigo (Infectious Disease) - Drugs in Development, 2021
발행일 : 2021년 09월 페이지 정보 : 영문 45 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

농가진은 매우 감염성이 높은 피부병입니다. 농가진은 2개의 박테리아, 화농렌사구균, 황색포도상구균에 기인합니다. 징후는 유체를 채운 물집, 가려운 발진, 피부 장애, 및 개인 림프절입니다. 위험요인은 피부와 피부의 접촉, 피부 상처, 당뇨병이나 면역부전 이환 등입니다. 치료에는 항생물질을 사용합니다.

농가진(Impetigo) 치료제 개발 상황에 대해 조사 분석했으며, 파이프라인 제품 개요, 주요 치료제 개발 참여 기업 및 약제 개요, 최신 파이프라인 동향 등의 정보를 전해드립니다.

서론

  • 조사 범위

농가진 개요

치료제 개발

  • 파이프라인 제품 개요
  • 기업별 파이프라인
  • 대학/연구기관에서 개발된 파이프라인
  • 기업에서 개발중인 제품
  • 대학/연구기관에서 개발중인 제품

치료제 평가

  • 표적별
  • 작용기전별
  • 투여 경로별
  • 분자 종류별

치료제 개발 참여 기업

  • Foamix Pharmaceuticals Ltd.
  • Laboratories Ojer Pharma S.L.
  • Lytix Biopharma AS
  • Toyama Chemical Co., Ltd.

치료제 평가

  • Destiny Pharma Ltd
  • Foamix Pharmaceuticals Ltd
  • Laboratories Ojer Pharma SL
  • Lytix Biopharma AS
  • Toyama Chemical Co Ltd

약제 프로파일

휴지 상태인 프로젝트

개발이 중지된 제품

제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

도표

LSH 17.07.31

List of Tables

List of Tables

  • Number of Products under Development for Impetigo, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Impetigo - Pipeline by FUJIFILM Toyama Chemical Co Ltd, 2021
  • Impetigo - Pipeline by Laboratories Ojer Pharma SL, 2021
  • Impetigo - Pipeline by Next Science Ltd, 2021
  • Impetigo - Pipeline by Union Therapeutics AS, 2021
  • Impetigo - Pipeline by Vaxcyte Inc, 2021
  • Impetigo - Dormant Projects, 2021
  • Impetigo - Discontinued Products, 2021

List of Figures

List of Figures

  • Number of Products under Development for Impetigo, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products by Targets, 2021
  • Number of Products by Stage and Targets, 2021
  • Number of Products by Mechanism of Actions, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Impetigo - Drugs In Development, 2021, provides an overview of the Impetigo (Infectious Disease) pipeline landscape.Impetigo is a highly contagious skin condition. Impetigo is caused by two bacteria streptococcus pyogenes and staphylococcus aureus. Symptoms include fluid-filled blisters, itchy rash, skin lesions and swollen lymph nodes. Risk factors include skin-to-skin contact, injury to the skin, having diabetes and having a compromised immune system. Treatment includes antibiotics.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Impetigo - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Impetigo (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Impetigo (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Impetigo and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Preclinical and Unknown stages are 1, 1, 1, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Impetigo (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Impetigo (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Impetigo (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Impetigo (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Impetigo (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Impetigo (Infectious Disease)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Impetigo (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Impetigo (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Impetigo - Overview
  • Impetigo - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Impetigo - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Impetigo - Companies Involved in Therapeutics Development
  • FUJIFILM Toyama Chemical Co Ltd
  • Laboratories Ojer Pharma SL
  • Next Science Ltd
  • Union Therapeutics AS
  • Vaxcyte Inc
  • Impetigo - Drug Profiles
  • Drug for Impetigo - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • mupirocin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • niclosamide - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ozenoxacin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Recombinant Enzyme to Disrupt Bacterial Cell Wall for Impetigo - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Synthetic Peptides for Infectious Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • VAX-24 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Impetigo - Dormant Projects
  • Impetigo - Discontinued Products
  • Impetigo - Product Development Milestones
  • Featured News & Press Releases
  • Mar 05, 2018: Newly Approved Treatment for Impetigo to be Commercialized by Cutanea Life Sciences
  • Jan 08, 2018: Cipher Pharmaceuticals Announces Canadian Launch of OZANEX (ozenoxacin cream 1%), a Novel Topical Antibiotic
  • Dec 14, 2017: Medimetriks Pharmaceuticals Receives FDA Approval for Xepi (ozenoxacin) Cream, 1%, a Novel Topical Antibiotic for Impetigo
  • May 08, 2017: Cipher Pharmaceuticals Receives Health Canada Approval of OZANEX (ozenoxacin cream 1%)
  • Jul 12, 2016: Cipher Pharmaceuticals announces Ozenoxacin accepted for review by Health Canada
  • Jun 27, 2016: Medimetriks Pharmaceuticals New Drug Application for Ozenoxacin Cream, 1% Accepted for Review by FDA
  • Jun 27, 2016: Medimetriks Pharmaceuticals Submits a New Drug Application to FDA for Ozenoxacin Cream, 1%, a Novel Impetigo Treatment
  • Jun 12, 2014: Medimetriks Pharmaceuticals Announces that the Second Phase III Study for Ozenoxacin has been Initiated by Ferrer
  • Jun 05, 2013: Ferrer Completes Phase III Clinical Trial Of Ozenoxacin In Adult And Pediatric Patients With Impetigo
  • Oct 05, 2012: Ferrer Successfully Completes Absorption, Tolerability And Safety Study In Juveniles As Young As Two Months Of Age For New Antibacterial Compound Ozenoxacin
  • Jan 19, 2012: Ferrer Initiates Phase III Clinical Studies For Ozenoxacin In Development As Topical Treatment For Impetigo And Other Infectious Dermatological Conditions
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q